CO2023011907A2 - Anticuerpo triespecífico dirigido a bcma, gprc5d, y cd3 - Google Patents

Anticuerpo triespecífico dirigido a bcma, gprc5d, y cd3

Info

Publication number
CO2023011907A2
CO2023011907A2 CONC2023/0011907A CO2023011907A CO2023011907A2 CO 2023011907 A2 CO2023011907 A2 CO 2023011907A2 CO 2023011907 A CO2023011907 A CO 2023011907A CO 2023011907 A2 CO2023011907 A2 CO 2023011907A2
Authority
CO
Colombia
Prior art keywords
antigen
binding fragments
antibodies
multispecific
bcma
Prior art date
Application number
CONC2023/0011907A
Other languages
English (en)
Inventor
Kodandaram Pillarisetti
Leopoldo Luistro
Ulrike Philippar
Sanjaya Singh
Ricardo Marcos Attar
Scott Ronald Brodeur
Rajkumar Ganesan
Danlin Dan Qing Yang
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CO2023011907A2 publication Critical patent/CO2023011907A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente descripción se proporcionan anticuerpos multiespecíficos que se unen a BCMA, GPRC5D y CD3 y fragmentos de unión al antígeno multiespecíficos de estos. Además, se describen polinucleótidos relacionados que tienen la capacidad de codificar anticuerpos multiespecíficos o fragmentos de unión al antígeno multiespecíficos proporcionados, células que expresan anticuerpos multiespecíficos o fragmentos de unión al antígeno multiespecíficos proporcionados, así como vectores asociados y anticuerpos multiespecíficos o fragmentos de unión al antígeno multiespecíficos marcados de forma detectable. Adicionalmente, se describen métodos para producir y usar los anticuerpos multiespecíficos y los fragmentos de unión al antígeno multiespecíficos proporcionados. En la presente invención se proporcionan además anticuerpos que se unen a BCMA y fragmentos de unión al antígeno de estos. Además, se describen polinucleótidos relacionados que tienen la capacidad de codificar anticuerpos específicos para BCMA o fragmentos de unión al antígeno proporcionados, células que expresan anticuerpos específicos para BCMA o fragmentos de unión al antígeno proporcionados, así como vectores asociados y anticuerpos específicos para BCMA o fragmentos de unión al antígeno marcados de forma detectable. Adicionalmente, se describen métodos para producir y usar los anticuerpos específicos para BCMA y los fragmentos de unión al antígeno proporcionados.
CONC2023/0011907A 2021-02-16 2023-09-07 Anticuerpo triespecífico dirigido a bcma, gprc5d, y cd3 CO2023011907A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163149921P 2021-02-16 2021-02-16
PCT/EP2022/053651 WO2022175255A2 (en) 2021-02-16 2022-02-15 Trispecific antibody targeting bcma, gprc5d, and cd3

Publications (1)

Publication Number Publication Date
CO2023011907A2 true CO2023011907A2 (es) 2023-09-18

Family

ID=80445956

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0011907A CO2023011907A2 (es) 2021-02-16 2023-09-07 Anticuerpo triespecífico dirigido a bcma, gprc5d, y cd3

Country Status (20)

Country Link
US (1) US20220267438A1 (es)
EP (1) EP4294528A2 (es)
JP (1) JP2024507180A (es)
KR (1) KR20230146578A (es)
CN (1) CN117279953A (es)
AR (1) AR124882A1 (es)
AU (1) AU2022221884A1 (es)
BR (1) BR112023016121A2 (es)
CA (1) CA3211163A1 (es)
CL (1) CL2023002382A1 (es)
CO (1) CO2023011907A2 (es)
CR (1) CR20230398A (es)
DO (1) DOP2023000158A (es)
EC (1) ECSP23069904A (es)
IL (1) IL305144A (es)
MX (1) MX2023009566A (es)
PE (1) PE20241170A1 (es)
TW (1) TW202302636A (es)
UY (1) UY39634A (es)
WO (1) WO2022175255A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3127025A1 (en) * 2019-01-18 2020-07-23 Janssen Biotech, Inc. Gprc5d chimeric antigen receptors and cells expressing the same
WO2023236889A1 (zh) * 2022-06-06 2023-12-14 山东先声生物制药有限公司 靶向bcma、gprc5d和t细胞的多特异性抗体及其应用
CN118414351A (zh) * 2022-09-09 2024-07-30 北京天广实生物技术股份有限公司 结合bcma、gprc5d和cd3的多特异性抗体及其用途
WO2024079015A1 (en) * 2022-10-10 2024-04-18 F. Hoffmann-La Roche Ag Combination therapy of a gprc5d tcb and imids
CN117924485A (zh) * 2022-10-25 2024-04-26 上海祥耀生物科技有限责任公司 一种抗gprc5d的多特异性抗体
WO2024165030A1 (zh) * 2023-02-07 2024-08-15 上海齐鲁制药研究中心有限公司 三特异性抗原结合分子及其应用
WO2024168192A1 (en) * 2023-02-10 2024-08-15 Celgene Corporation Assessment of bcma in biological samples
WO2024180469A1 (en) * 2023-02-28 2024-09-06 Janssen Biotech, Inc. Compositions comprising a bispecific gprc5d/cd3 antibody

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020142000A1 (en) 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2001024812A1 (en) 1999-10-06 2001-04-12 N.V. Nutricia USE OF TRANSFORMING GROWTH FACTOR β AND GROWTH FACTORS IN THE TREATMENT AND PREVENTION OF DISEASES OF THE INTESTINAL MUCOSA
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
EP2301971A1 (en) 2001-02-20 2011-03-30 ZymoGenetics, L.L.C. Antibodies that bind both BCMA and TACI
US20060204493A1 (en) 2004-09-02 2006-09-14 Genentech, Inc. Heteromultimeric molecules
WO2006106905A1 (ja) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha 会合制御によるポリペプチド製造方法
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
EP1940881B1 (en) 2005-10-11 2016-11-30 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
EP1973576B1 (en) 2005-11-28 2019-05-15 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
US20090182127A1 (en) 2006-06-22 2009-07-16 Novo Nordisk A/S Production of Bispecific Antibodies
ES2432792T5 (es) 2007-04-03 2023-01-16 Amgen Res Munich Gmbh Dominio de unión a CD3-épsilon específico de especies cruzadas
HUE040467T2 (hu) 2007-04-03 2019-03-28 Amgen Res Munich Gmbh Keresztfaj-specifikus kötõdomén
WO2008119566A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific bispecific binders
AU2009299794B2 (en) 2008-10-01 2015-08-13 Amgen Research (Munich) Gmbh Cross-species-specific single domain bispecific single chain antibody
ME02485B (me) 2008-10-01 2017-02-20 Amgen Res Munich Gmbh Bispecifično jednolančano protutijelo psmaxcd3 s međuvrsnom specifičnošću
EP2352763B2 (en) 2008-10-01 2022-09-21 Amgen Research (Munich) GmbH Bispecific single chain antibodies with specificity for high molecular weight target antigens
DK2356269T3 (en) 2008-10-31 2016-08-15 Janssen Biotech Inc FIBRONECTIN TYPE III DOMAIN-BASED SCAFFOLD COMPOSITIONS, PROCEDURES AND APPLICATIONS
WO2010093627A2 (en) 2009-02-12 2010-08-19 Centocor Ortho Biotech Inc. Fibronectin type iii domain based scaffold compositions, methods and uses
LT2406284T (lt) 2009-03-10 2016-10-10 Biogen Ma Inc. Antikūnai prieš b ląstelių subrendimo antigenus
ES2708124T3 (es) 2009-04-27 2019-04-08 Oncomed Pharm Inc Procedimiento para preparar moléculas heteromultiméricas
CN103097417B (zh) 2010-04-20 2019-04-09 根马布股份公司 含异二聚体抗体fc的蛋白及其制备方法
AU2011325833C1 (en) 2010-11-05 2017-07-13 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
CA2854233C (en) 2011-11-04 2020-05-12 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
SG11201704552TA (en) 2014-12-05 2017-07-28 Memorial Sloan Kettering Cancer Center Antibodies targeting g-protein coupled receptor and methods of use
MA53750A (fr) 2015-08-17 2021-09-15 Janssen Pharmaceutica Nv Anticorps anti-bcma, molécules de liaison d'antigène bispécifiques qui se lient au bcma et cd3 et leurs utilisations
TWI781108B (zh) 2016-07-20 2022-10-21 比利時商健生藥品公司 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
RU2019128134A (ru) 2017-02-07 2021-03-09 Дайити Санкио Компани, Лимитед Антитело против gprc5d и молекула, содержащая антитело
CN111417652B (zh) 2017-09-22 2023-10-20 凯德药业股份有限公司 嵌合多肽及其用途
TWI829667B (zh) 2018-02-09 2024-01-21 瑞士商赫孚孟拉羅股份公司 結合gprc5d之抗體
MX2020012286A (es) * 2018-05-16 2021-04-28 Janssen Biotech Inc Metodos para tratar canceres y potenciar la eficacia de agentes terapeuticos para el redireccionamiento de celulas t.
US20200109195A1 (en) * 2018-05-21 2020-04-09 Compass Therapeutics Llc Compositions and methods for enhancing the killing of target cells by nk cells
JOP20190116A1 (ar) 2018-05-24 2019-11-24 Janssen Biotech Inc الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
CA3127025A1 (en) * 2019-01-18 2020-07-23 Janssen Biotech, Inc. Gprc5d chimeric antigen receptors and cells expressing the same
US20210284731A1 (en) * 2020-03-13 2021-09-16 Janssen Biotech, Inc. Methods and materials for modulating an immune response
TW202227495A (zh) * 2020-09-11 2022-07-16 美商健生生物科技公司 用於調節β鏈介導之免疫的方法及組成物
IL301242A (en) * 2020-09-11 2023-05-01 Janssen Biotech Inc Multispecific vaccine targeting molecules and their uses
CN112028996B (zh) * 2020-10-30 2021-01-22 南京北恒生物科技有限公司 靶向bcma的单域抗体及其用途

Also Published As

Publication number Publication date
BR112023016121A2 (pt) 2023-11-28
TW202302636A (zh) 2023-01-16
US20220267438A1 (en) 2022-08-25
UY39634A (es) 2022-08-31
AU2022221884A1 (en) 2023-10-05
CR20230398A (es) 2023-11-15
WO2022175255A3 (en) 2022-09-29
WO2022175255A2 (en) 2022-08-25
KR20230146578A (ko) 2023-10-19
EP4294528A2 (en) 2023-12-27
DOP2023000158A (es) 2024-02-29
JP2024507180A (ja) 2024-02-16
CL2023002382A1 (es) 2024-03-15
IL305144A (en) 2023-10-01
AR124882A1 (es) 2023-05-17
MX2023009566A (es) 2023-10-24
PE20241170A1 (es) 2024-05-28
CN117279953A (zh) 2023-12-22
ECSP23069904A (es) 2023-10-31
CA3211163A1 (en) 2022-08-25

Similar Documents

Publication Publication Date Title
CO2023011907A2 (es) Anticuerpo triespecífico dirigido a bcma, gprc5d, y cd3
UY37340A (es) Antianticuerpos gprc5d, moléculas de unión al antígeno biespecíficas que se unen a gprc5d y cd3, y usos de estas
CL2023000907A1 (es) Anticuerpos de unión a gprc5d
UY36974A (es) Anticuerpos anti-il1rap, moléculas de unión a antígenos biespecíficas que se unen a il1rap y cd3, y usos de estas
UY36859A (es) Anticuerpos anti-bcma, moléculas de unión a antígenos biespecíficas que se unen a bcma y cd3, y usos de estas
CL2020003031A1 (es) Agentes aglutinantes del psma y usos de estos.
CO2017008462A2 (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
PE20180484A1 (es) Moleculas biespecificas de union a antigeno activadoras de celulas t
CO2019006500A2 (es) Anticuerpos biespecíficos que se unen al factor de coagulación ix y al factor de coagulación x
CL2018000502A1 (es) Anticuerpos biespecíficos para pd1 y tim3 útiles como inmunomoduladores o en el tratamiento del cáncer.
CO2023013511A2 (es) Anticuerpo triespecífico dirigido a cd79b, cd20, y cd3
PE20170263A1 (es) Moleculas biespecificas de union a antigeno activadoras de celulas t
UY36289A (es) ANTICUERPOS MONOCLONALES QUE ENLAZAN INMUNOESPECIFICAMENTE A CD123 y COMPOSICIONES QUE LOS CONTIENEN
CO2017010495A2 (es) Anticuerpos que se unen a bcma y/o cd3
UY37083A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso
BR112019002168A2 (pt) anticorpos trivalentes bispecíficos ligantes a claudina6 ou claudina18.2 e cd3 para o tratamento de doenças cancerígenas que expressam claudina
AR106365A1 (es) Moléculas biespecíficas de unión a antígeno activadoras de células t
CO7250445A2 (es) Proteínas de unión a antígeno st2
AR119393A1 (es) Anticuerpos que se unen a nkg2d
CL2020001629A1 (es) Anticuerpos de unión a hla-a2/wt1.
AR125211A1 (es) Anticuerpos triespecíficos dirigidos a cd79b, cd20 y cd3
CO2021005178A2 (es) Anticuerpo monoclonal que se une específicamente al antígeno cd20
AR118080A2 (es) Proteínas de unión a antígeno dirigidas contra el receptor
AR107834A1 (es) Anticuerpos que se unen al factor de necrosis tumoral inducido por glucocorticoides (gitr), métodos y usos
AR121333A1 (es) Moléculas de unión biespecíficas